That means you cannot legitimately place 10.8% for cagrilintide next to 24.2% for retatrutide and declare a winner, because those numbers come from different trials, different populations, different durations (26 vs 48 weeks), different doses, and critically a monotherapy figure for one versus a monotherapy figure for the other, while cagrilintides strongest data are actually as a combination
These practices can also improve body composition, metabolic health, and insulin sensitivity, which ultimately leads to more sustainable weight loss and better health in the long haul.
122(Pt 24), 45164525
Regulatory status: FDA-approved in 1959 as a short-term adjunct for weight reduction in adults with exogenous obesity
Gabe MBN, Skov-Jeppesen K, Gasbjerg LS, et al
Sublingual administration offers a middle ground, providing better absorption than oral routes while avoiding injection discomfort